Maximus, Inc.
—- Market cap
- $2.96B
- Debt
- —
- Cash
- −$222.35M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: MMS stock price vs CACI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CACI's multiple
Needs CACI P/E.
Implied fair value · at MMS's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Maximus, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CACI INTERNATIONAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
MMS vs ACN
INTERNATIONAL BUSINESS MACHINES CORP
MMS vs IBM
ROLLINS INC
MMS vs ROL
CINTAS CORP
MMS vs CTAS
IRON MOUNTAIN INC
MMS vs IRM
Science Applications International Corp
MMS vs SAIC
KBR, INC.
MMS vs KBR
Booz Allen Hamilton Holding Corp
MMS vs BAH
Leidos Holdings, Inc.
MMS vs LDOS
JACOBS SOLUTIONS INC.
MMS vs J
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MMS can sustain its superior margin profile while closing part of the growth gap with CACI, then MMS looks attractive to buy because it trades at roughly half CACI’s P/E and EV/EBITDA despite stronger ROIC and lower net leverage.
MMS trades at a steep discount to CACI despite operating with better margins and far stronger ROIC. CACI-implied valuation range of $131.75-$151.51 versus MMS at $60.25 suggests the market is valuing CACI’s faster growth far more richly than MMS’s current earnings power.
Supporting Metrics